SCHEMBL2983547

SCHEMBL2983547

CC1(C)C(=O)NC(=O)N1CCNc1nccc(-c2cc3cc(NC(=O)c4ccncc4)ccc3s2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 9/20 0.41
CHUK O15111 7/20 0.41
IKBKG Q9Y6K9 7/20 0.41
PDGFRB P09619 4/20 0.39
KDR P35968 4/20 0.39
ABL1 P00519 1/20 0.38
BCR P11274 1/20 0.38
SRC P12931 1/20 0.38
PRKCA P17252 1/20 0.38
PRKCD Q05655 1/20 0.38
MAPK14 Q16539 2/20 0.36
MEN1 O00255 1/20 0.35
RECQL P46063 1/20 0.35
BLM P54132 1/20 0.35
KMT2A Q03164 1/20 0.35
PRKCZ Q05513 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
HDAC1 Q13547 1/20 0.35
SYK P43405 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2984268 0.94 PDGFRB (0.46) IKBKBCHUKIKBKGPDGFRBKDR
SCHEMBL2990209 0.91 PDGFRB (0.43) IKBKBCHUKIKBKGPDGFRBKDR
SCHEMBL2977942 0.90 PDGFRB (0.39) IKBKBCHUKIKBKGPDGFRBKDR
SCHEMBL2983663 0.90 IKBKB (0.39) IKBKBCHUKIKBKGPDGFRBABL1
SCHEMBL3177282 0.89 IKBKB (0.41) IKBKBCHUKIKBKGHDAC1SYK
SCHEMBL2986419 0.89 AURKA (0.42) IKBKBCHUKIKBKGPDGFRBKDR
SCHEMBL2987595 0.89 IKBKB (0.41) IKBKBCHUKIKBKGPDGFRBKDR
SCHEMBL2988565 0.88 IKBKB (0.35) IKBKBCHUKIKBKGPDGFRBKDR
SCHEMBL2975941 0.88 IKBKB (0.38) IKBKBCHUKIKBKGPDGFRBKDR
SCHEMBL2983796 0.88 IKBKB (0.38) IKBKBCHUKIKBKGMEN1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831207-B1 AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS AMGEN INC (US) 2012-11-14 EP disclosed
US-7858785-B2 Aminopyrimidine compounds and methods of use AMGEN INC. (US) 2010-12-28 US disclosed
US-7786132-B2 Aminopyrimidine compounds and methods of use AMGEN INC. (US) 2010-08-31 US disclosed
US-20100010014-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2010-01-14 US disclosed
EP-1831207-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-09-12 EP disclosed
US-20070185133-A1 Aminopyrimidine compounds and methods of use AMGEN, INC. (US) 2007-08-09 US disclosed
WO-2006066172-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE AMGEN, INC. (US) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010014-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE PLK1, TYMP, TK2 IKBKB 1952/4885CHUK 1311/4885IKBKG 2049/4885
US-20070185133-A1 Aminopyrimidine compounds and methods of use PLK1, TYMP, TK2 IKBKB 1952/4885CHUK 1311/4885IKBKG 2049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.